NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has integrated Arabic as the second international language to its Intelligent Fingerprinting Drug Screening System as part of the Company's multilingual upgrade. The addition of Arabic follows INBS's previously announced expansion plans in the Middle East in early 2025, through its ...

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced its participation as a gold sponsor at the 2025 National Drug and Alcohol Screening Association (NDASA) Conference and Trade Show, taking place from April 1 – 4 in Jacksonville, Florida. Daniel Brown, Head of Clinical Affairs at Intelligent Bio Solutions, will present at the Internation ...

Company Overview - Intelligent Bio Solutions Inc. (INBS) has secured a key patent in the United States for its Intelligent Fingerprinting Drug Screening Cartridge, marking its sixth active patent in the U.S. [1][4] - The company aims to enhance its competitive edge and accelerate the commercialization of its technology as it approaches market launch [2][4]. Market Position and Financials - INBS currently has a market capitalization of $11.9 billion and anticipates an earnings growth of 80.4% in 2025 [5]. - Following the patent announcement, INBS shares fell by 5.1%, closing at $1.67, with a 6-month decline of 8.2%, compared to the industry's 13.2% decline [3]. Product and Technology - The Intelligent Fingerprinting Drug Screening Cartridge is a non-invasive drug testing solution that detects drug metabolites through fingerprint sweat analysis, offering rapid and hygienic screening [9][10]. - The cartridge collects a small sweat sample and provides results in minutes, eliminating the need for invasive sample collection and reducing contamination risks [10]. Intellectual Property and Competitive Advantage - INBS has developed a robust intellectual property portfolio, with six active U.S. patents covering various aspects of its drug screening technology [6][8]. - The strengthened IP protection reduces imitation risks and reinforces investor confidence in the company's long-term growth potential [4]. Industry Prospects - The global drug screening market was valued at $7.7 billion in 2023 and is projected to grow at a CAGR of 16.6%, reaching $19.5 billion by 2029, positioning INBS to capitalize on this growth with its patented technology [11].

INBS set to capitalize on growing Spanish Drug Testing Market, anticipated to reach $448 million by 2030 Major Spanish accounts currently require 1,000 drug testing cartridges per month NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced it has expanded access to its fingerprint drug testing in Spain and Andorra through a strategic coll ...

Core Viewpoint - Intelligent Bio Solutions Inc. has been granted its sixth U.S. patent, enhancing its intellectual property portfolio and competitive position as it prepares to enter the multi-billion dollar U.S. drug screening market in 2025 [1][3]. Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System [4]. - The company aims to revolutionize portable testing via fingerprint sweat analysis, which is designed to be hygienic and cost-effective [4]. Patent Details - The newly granted U.S. Patent No. 12259385 pertains to the proprietary lateral flow test strip within the Drug Screening Cartridge, ensuring protection for all current and future products developed by the company [2]. - This patent is fundamental to the company's testing system, which utilizes lateral flow technology to detect drugs in fingerprint sweat [2]. Market Position and Strategy - The U.S. market is identified as a key focus for the company, with plans to enter this market in 2025, supported by the recent FDA 510(k) submission in December 2024 [3]. - The Intelligent Fingerprinting Drug Testing Solution addresses the growing demand for drug testing in safety-sensitive industries, providing a non-invasive alternative that supports employee well-being and compliance [3]. Target Industries - Current customer segments outside the U.S. include construction, manufacturing, engineering, transport and logistics, drug treatment organizations, and coroners [4].

Core Viewpoint - Intelligent Bio Solutions Inc. is progressing towards the FDA clearance for its Intelligent Fingerprint Drug Screening System, aiming for a U.S. market launch in 2025, specifically targeting opiate testing for codeine [1][2][5]. FDA Clearance Process - The company submitted its 510(k) premarket notification to the FDA on December 18, 2024, which is classified as a Class II device requiring a 510(k) submission [2]. - The FDA has initiated a 90-day review period for the submission, which may extend to three to six months or longer if additional data is requested [4]. Performance Data and Validation - The 510(k) submission included performance data showing a 94.1% accuracy rate and validation studies indicating that fingerprint sweat is a reliable sample matrix for drug detection [3]. - The quantitative pharmacokinetic data aligns closely with blood analysis, demonstrating the system's reliability and usability [3]. Market Potential - The company is preparing to enter the multi-billion-dollar U.S. market in 2025 and is also pursuing FDA clearance for additional drug classes [4]. - The Intelligent Fingerprint Drug Screening System is designed for rapid, non-invasive testing, with results available in under ten minutes, making it suitable for safety-critical industries [6]. Global Presence - The company's full panel test is already adopted in 19 countries with over 400 accounts globally, indicating a strong international presence [4].

Core Viewpoint - Intelligent Bio Solutions Inc. is progressing towards the FDA clearance for its Intelligent Fingerprint Drug Screening System, aiming for a U.S. market launch in 2025, specifically targeting opiate testing for codeine [1][2][5]. FDA Clearance Process - The company submitted its 510(k) premarket notification to the FDA on December 18, 2024, marking a significant milestone for entering the U.S. market [2]. - The FDA classified the system as a Class II device, requiring a 510(k) submission, which initiated a 90-day review period [2][4]. - The FDA has issued an Additional Information (AI) request, pausing the review clock, and the company is currently addressing this request [4]. Performance Data - The 510(k) submission included performance data showing a 94.1% accuracy rate and validation studies indicating that fingerprint sweat is a reliable sample matrix for drug detection [3]. - The pharmacokinetic (PK) study results align closely with blood data, demonstrating the system's reliability and usability [3]. Market Potential - The company is preparing for a significant entry into the multi-billion-dollar U.S. market in 2025 and is also pursuing FDA clearance for additional drug classes [4]. - The Intelligent Fingerprinting Drug Screening System is designed for rapid, non-invasive testing, with results available in under ten minutes, making it suitable for safety-critical industries [6]. Global Presence - The company's full panel test is already adopted in 19 countries with over 400 accounts globally, indicating a strong international presence [4].

Core Insights - Intelligent Bio Solutions Inc. (INBS) is set to receive its sixth patent in the U.S., enhancing its intellectual property portfolio related to its Intelligent Fingerprinting Drug Testing Solution [1][2] - The patent will protect INBS's lateral flow technology, crucial for its market entry strategy in the U.S. drug screening market [2][3] - The demand for non-invasive drug testing solutions is increasing as industries focus on workplace safety and compliance, positioning INBS favorably for market transformation [3] Company Overview - Intelligent Bio Solutions Inc. specializes in rapid, non-invasive testing solutions, particularly through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat [5] - The system screens for commonly used drugs in the workplace, including opiates, cocaine, methamphetamine, and cannabis, with results available in under ten minutes [5] - Current customer segments outside the U.S. include construction, manufacturing, transport, drug treatment organizations, and coroners [5]

Company Overview - Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company focused on delivering innovative, rapid, non-invasive testing solutions [3] - The company’s Intelligent Fingerprinting Drug Screening System utilizes fingerprint sweat analysis, aiming to revolutionize portable testing with potential applications in various fields [3] - The system is designed to be hygienic and cost-effective, screening for recent drug use, including opiates, cocaine, methamphetamine, and cannabis [3] Conference Participation - The management team of Intelligent Bio Solutions Inc. will participate in the iAccess Alpha Virtual Best Ideas Spring Conference on March 25 and 26, 2025 [1] - The presentation is scheduled for March 25th at 11:00 a.m. ET, with one-on-one meetings available during the conference [2] Target Markets - Current customer segments outside the US include construction, manufacturing, engineering, transport and logistics firms, drug treatment organizations, and coroners [3]

Core Viewpoint - Intelligent Bio Solutions Inc. has successfully closed a public offering of 1,500,000 shares at a price of $2.00 per share, raising approximately $3.0 million in gross proceeds [1]. Company Overview - Intelligent Bio Solutions Inc. is a medical technology company focused on delivering innovative, rapid, non-invasive testing solutions. The company aims to transform portable testing through its Intelligent Fingerprinting Drug Screening System, which analyzes fingerprint sweat for drug use [5]. - The system is designed to be hygienic and cost-effective, screening for drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. It allows for sample collection in seconds and provides results in under ten minutes, making it a valuable tool for employers in safety-critical industries [5]. Offering Details - The public offering included the full exercise of the underwriter's option to purchase an additional 195,652 shares, which contributed to the total gross proceeds [1]. - Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager for the offering [2]. - The offering was conducted under a shelf registration statement filed with the SEC, which was declared effective in April 2022 [3].